RxDoctor Payments Data

Cheryl Conway, APRN

Family · Owenton, KYNPI 1366847485

Payments from drug & device makers

$4,167in general payments, 2019–2025

Across 230 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$704
  • Lilly USA, LLC$629
  • AstraZeneca$515
  • AbbVie$479
  • Boehringer Ingelheim$400
  • Amgen$279
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,167 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,228
Medicare patients
30
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol22$19,031
MounjaroTirzepatide12$12,529
VascepaIcosapent Ethyl14$7,630
Albuterol Sulfate HfaAlbuterol Sulfate16$529
Metoprolol Succinate53$358
Ezetimibe44$293
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$193
Levothyroxine Sodium23$184
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16$163
Trazodone Hcl29$131
Amlodipine Besylate27$131
Fluticasone Propionate13$117
Losartan Potassium11$117
Duloxetine Hcl15$109
Cephalexin23$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$515$19,03122 claims
Lilly USA, LLCMounjaro$629$12,52912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Owenton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →